Please login to the form below

Not currently logged in
Email:
Password:

sepsis

This page shows the latest sepsis news and features for those working in and with pharma, biotech and healthcare.

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

TiGenix has another adipose-derived product, Cx611, which is currently undergoing a phase I/II trial in severe sepsis.

Latest news

More from news
Approximately 5 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    The option is exercisable on completion of the phase II studies in acute kidney injury related to sepsis.

  • The impending threat of antibiotic resistance The impending threat of antibiotic resistance

    Causes of death by infection in the pre-antibiotic era . Childbirth. 9 women in 1000 die in childbirth - 40% from sepsis. ... Every year 35, 000 people die from sepsis in the UK – some of these deaths are from antibiotic resistant infections.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • TiGenix appoints Dr Marie Paule Richard TiGenix appoints Dr Marie Paule Richard

    In her new role Richard will be responsible for the development of several products in Europe and the US, including rheumatoid arthritis and severe sepsis candidate Cx611 and Cx601, which is

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics